Frequency of CYP450 enzyme gene polymorphisms in the Greek population: Review of the literature, original findings and clinical significance

Drug Metabolism and Drug Interactions

Volumn 29, Issue 4, 2014, Pages 235-248

  Ragia, Georgia ^a   Giannakopoulou, Efstathia ^a   Karaglani, Makrina ^a   Karantza, Ioanna Maria ^a   Tavridou, Anna ^a,b   Manolopoulos, Vangelis G ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Academic General Hospital Alexandroupolis   (Greece)

Author keywords

CYP1A2; CYP2C19; CYP2C9; CYP2D6; CYP3A4; CYP3A5; CYP450; Greece; Polymorphisms

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

AEROBIC METABOLISM; CYP1A2 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; CYP3A5 GENE; CYP450 GENE; DRUG METABOLISM; ETHNICITY; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GREEK (PEOPLE); HUMAN; PHARMACOGENOMICS; PREVALENCE; PROTEIN FAMILY; REVIEW; ETHNIC GROUP; ETHNOLOGY; GENETICS; HEALTH SURVEY; PHARMACOGENETICS; PROCEDURES; TRENDS;

CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE;

EID: 84925387922     PISSN: 07925077     EISSN: 21910162     Source Type: Journal    
DOI: 10.1515/dmdi-2014-0006     Document Type: Review

References (106)

1. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med 2007;45:801-14.
2. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
3. Stathias V, Sotiris GR, Karagiannidis I, Bourikas G, Martinis G, Papazoglou D, et al. Exploring genomic structure differences and similarities between the Greek and European HapMap populations: implications for association studies. Ann Hum Genet 2012;76:472-83.
4. United States Board on Geographic Names, United States, Defense Mapping Agency. Gazetteer of conventional names: names approved by the United States Board on Geographic Names. 3rd ed. Washington DC, USA, 1989.
5. Prentice AM, Rayco-Solon P, Moore SE. Insights from the developing world: thrifty genotypes and thrifty phenotypes. Proc Nutr Soc 2005;64:153-61.
6. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003;95:1297-300.
7. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009;48:761-804.
8. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48:689-723.
9. Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 2009;12:334-61.
10. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2007;21:419-26.
11. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19∗17 discovery: the case of Greece. Pharmacogenomics 2009;10:43-9.
12. Kimiskidis VK, Niopas I, Firinidis PD, Kanaze FI, Gabrieli C, Kazis D, et al. Frequency distribution of dextromethorphan O-demethylation in a Greek population. Int J Clin Pharmacol Ther 2005;43:150-3.
13. Manolopoulos VG, Ragia G, Alevizopoulos G. Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. Drug Metabol Drug Interact 2012;27:19-31.
14. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195-200.
15. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med 2011;28:1093-102.
16. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010;62:1159-69.
17. Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 2006;24:381-5.
18. Garcia-Martin E, Martinez C, Ladero JM, Gamito FJ, Agundez JA. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001;57:47-9.
19. Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003;59:221-5.
20. Boso V, Herrero MJ, Buso E, Galan J, Almenar L, Sanchez-Lazaro I, et al. Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population. Ther Drug Monit 2014;36:159-68.
21. Fontanellas A, Martinez-Fresno M, Garrido-Astray MC, Perucho T, Moran-Jimenez MJ, Garcia-Bravo M, et al. Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp Dermatol 2010;19:e326-8.
22. Serin A, Canan H, Alper B, Gulmen M. The frequencies of mutated alleles of CYP2D6 gene in a Turkish population. Forensic Sci Int 2012;222:332-4.
23. Koseler A, Ilcol YO, Ulus IH. Frequency of mutated allele CYP2D6∗4 in the Turkish population. Pharmacology 2007;79:203-6.
24. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66:185-92.
25. Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, et al. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 2012;68:629-36.
26. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999;48:409-15.
27. Bilgen T, Tosun O, Luleci G, Keser I. Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population. Genetika 2008;44:1133-6.
28. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003;44:425-8.
29. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304-12.
30. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4∗22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013;14:47-62.
31. Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001;57:717-22.
32. Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, et al. The influence of CYP2C19∗2 and ∗17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012;22:169-75.
33. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668-71.
34. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19∗17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogreltreated patients with coronary stent placement. Circulation 2010;121:512-8.
35. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, et al. CYP2C19∗17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009;115:391-6.
36. Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002;54:518-21.
37. Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, et al. The CYP3A4∗1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 2003;13:607-18.
38. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
39. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, et al. Linkage disequilibrium between the CYP2C19∗17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010;66:1199-205.
40. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest 2006;66:129-36.
41. Bathum L, Hansen TS, Horder M, Brosen K. A dual label oligonucleotide ligation assay for detection of the CYP2C19∗1, CYP2C19∗2, and CYP2C19∗3 alleles involving time-resolved fluorometry. Ther Drug Monit 1998;20:1-6.
42. Borst L, Wallerek S, Dalhoff K, Rasmussen KK, Wesenberg F, Wehner PS, et al. The impact of CYP3A5∗3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol 2011;86:477-83.
43. Christiansen L, Bygum A, Jensen A, Thomsen K, Brandrup F, Horder M, et al. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 2000;107:612-4.
44. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
45. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjoqvist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998;54:479-81.
46. Ramsjo M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010;66:871-7.
47. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999;254:628-31.
48. Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 2006;16:637-45.
49. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007;63:537-46.
50. Rideg O, Haber A, Botz L, Szucs F, Varnai R, Miseta A, et al. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell Biochem Funct 2011;29:562-8.
51. Sipeky C, Weber A, Szabo M, Melegh BI, Janicsek I, Tarlos G, et al. High prevalence of CYP2C19∗2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature. Mol Biol Rep 2013;40:4727-35.
52. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, et al. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis 2009;43:239-42.
53. Kristiansen W, Haugen TB, Witczak O, Andersen JM, Fossa SD, Aschim EL. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility. Int J Androl 2011;34:77-83.
54. Kersten H, Wyller TB, Molden E. Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs. Ther Drug Monit 2014;36:125-30.
55. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303-12.
56. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
57. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020839s044lbl.pdf.
58. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94:317-23.
59. Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19∗2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2012;129:441-6.
60. Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, et al. Impact of the proton pump inhibitors and CYP2C19∗2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thromb Res 2013;132:e105-11.
61. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, et al. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Int J Cardiol 2013;168:1594-6.
62. Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 2013;28:28-37.
63. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
64. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
65. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010;11:493-6.
66. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-303.
67. Markatos CN, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I, et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008;9:1631-8.
68. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011;12:1161-91.
69. Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A. Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population. Disease Markers 2013;35:641-6.
70. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9∗3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10:1781-7.
71. Ragia G, Tavridou A, Elens L, Van Schaik R, Manolopoulos V. CYP2C9∗2 allele increases risk for hypoglycemia in POR∗1/∗1 type 2 diabetic patients treated with sulfonylureas. Exp Clin Endocrinol Diabetes 2014;122:60-3.
72. Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract 2012;98:119-24.
73. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
74. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004;75:1059-69.
75. Pemberton TJ, Mehta NU, Witonsky D, Di Rienzo A, Allayee H, Conti DV, et al. Prevalence of common disease-associated variants in Asian Indians. BMC Genet 2008;9:13.
76. Bains RK, Kovacevic M, Plaster CA, Tarekegn A, Bekele E, Bradman NN, et al. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet 2013;14:34.
77. Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L, et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006;24:923-9.
78. Katsakiori PF, Papapetrou EP, Sakellaropoulos GC, Goumenos DS, Nikiforidis GC, Flordellis CS. Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach. Int J Med Sci 2010;7:94-100.
79. Katsakiori PF, Papapetrou EP, Goumenos DS, Nikiforidis GC, Flordellis CS. Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: an interaction study in CYP3A5 non-expressors, renal transplant recipients. Indian J Pharmacol 2011;43:385-8.
80. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14:523-5.
81. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007;47:87-93.
82. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1∗3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol 2011;51:181-8.
83. Kolovou G, Ragia G, Kolovou V, Mihas C, Katsiki N, Vasiliadis I, et al. Impact of CYP3A5 gene polymorphism on efficacy of simvastatin. The Open Cardiovasc Med J 2014;8:12-7.
84. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274-86.
85. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C>T polymorphism (CYP3A4∗22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 2013;38:349-54.
86. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. Aaps J 2009;11:481-94.
87. Sim SC. CYP1A2∗1E [corrected] contains the -163C> A substitution and is highly inducible. Pharmacogenet Genomics 2013;23:104-5.
88. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268-354.
89. Jernstrom H, Henningson M, Johansson U, Olsson H. Coffee intake and CYP1A2∗1F genotype predict breast volume in young women: implications for breast cancer. Br J Cancer 2008;99:1534-8.
90. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004;41:758-62.
91. Bozikas VP, Papakosta M, Niopas I, Karavatos A, Mirtsou-Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 2004;14:39-44.
92. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007;21:190-200.
93. Mastrogianni O, Gbandi E, Orphanidis A, Raikos N, Goutziomitrou E, Kolibianakis EM, et al. Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece. Drug Metab Pharmacokinet 2013 DOI http://dx.doi.org/10.2133/dmpk.DMPK-13-NT-092.
94. Pliarchopoulou K, Voutsinas G, Papaxoinis G, Florou K, Skondra M, Kostaki K, et al. Correlation of CYP1A1, GSTP1 and GSTM1 gene polymorphisms and lung cancer risk among smokers. Oncol Lett 2012;3:1301-6.
95. Agorastos T, Papadopoulos N, Lambropoulos AF, Chrisafi S, Mikos T, Goulis DG, et al. Glutathione-S-transferase M1 and T1 and cytochrome P1A1 genetic polymorphisms and susceptibility to cervical intraepithelial neoplasia in Greek women. Eur J Cancer Prev 2007;16:498-504.
96. Dialyna IA, Arvanitis DA, Spandidos DA. Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer. Int J Mol Med 2001;8:79-87.
97. Tsatsakis AM, Androutsopoulos VP, Zafiropoulos A, Babatsikou F, Alegakis T, Dialyna I, et al. Associations of xenobiotic-metabolizing enzyme genotypes PON1Q192R, PON1L55M and CYP1A1∗2A MspI with pathological symptoms of a rural population in south Greece. Xenobiotica 2011;41:914-25.
98. Tsatsakis AM, Zafiropoulos A, Tzatzarakis MN, Tzanakakis GN, Kafatos A. Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides. Toxicol Lett 2009;186:66-72.
99. Arvanitis DA, Koumantakis GE, Goumenou AG, Matalliotakis IM, Koumantakis EE, Spandidos DA. CYP1A1, CYP19, and GSTM1 polymorphisms increase the risk of endometriosis. Fertil Steril 2003;79(Suppl 1):S702-9.
100. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73:735-41.
101. Androulakis E, Tousoulis D, Papageorgiou N, Miliou A, Chatzistamatiou E, Moustakas G, et al. Effects of the C-344T aldosterone synthase gene variant on preclinical vascular alterations in essential hypertension. Int J Cardiol 2013;168:1605-6.
102. Litridis I, Kapnoulas N, Natisvili T, Agiannitopoulos K, Peraki O, Ntostis P, et al. Genetic variation in the CYP17 gene and recurrent spontaneous abortions. Arch Gynecol Obstet 2011;283:289-93.
103. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, et al. Polymorphism T-->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999;71:431-5.
104. Litos IK, Emmanouilidou E, Glynou KM, Laios E, Ioannou PC, Christopoulos TK, et al. Rapid genotyping of CYP2D6, CYP2C19 and TPMT polymorphisms by primer extension reaction in a dipstick format. Anal Bioanal Chem 2007;389:1849-57.
105. Toubanaki DK, Christopoulos TK, Ioannou PC, Gravanis A. Dry-reagent disposable biosensor for visual genotyping of single nucleotide polymorphisms by oligonucleotide ligation reaction: application to pharmacogenetic analysis. Hum Mutat 2008;29:1071-8.
106. Toubanaki DK, Christopoulos TK, Ioannou PC, Gravanis A. Visual genotyping of SNPs of drug-metabolizing enzymes by tetra-primer PCR coupled with a dry-reagent DNA biosensor. Pharmacogenomics 2009;10:495-504.